That option has been explored in several cases with additional supporting data, but it’s not clear from the regulatory guidances to fully support derisk a nitrosamines impurity from additional assessment.
Related to this, please look at the presentation that Andrew Teasdale did at the recent CRGC meeting ‘Hydrochlorothiazide – a twist in the tail’